# 18 International Forum on Mood and Anxiety Disorders

**Vienna** (Austria) 04 – 06 July 2019

Final Programme







www.ifmad.org/2019

Chairmen

Siegfried **Kasper** (Austria) Stuart A. **Montgomery** (UK) Allan H. **Young** (UK) Eduard **Vieta** (Spain)



### **WELCOME**

Dear Colleagues, dear Friends,

We are delighted to invite you to the 18<sup>th</sup> International Forum on Mood and Anxiety Disorders that will be held in July in Vienna.

IFMAD has a long and successful tradition of inviting international expert speakers on subjects which provide new insights in treatment of various psychiatric disorders. The meeting always takes place in a collegiate setting which allows for an open interaction between speakers, other experts present and the registrants both in the meeting room and in the intervals.

This year we expect a lively discussion on treatment resistant depression with new findings on rapid response within a day in TRD. The latest findings on the genetic basis of TRD will open the way to the use of personalized treatment of depression to reduce the chance of resistance developing. There will be overviews of the contribution of inflammation to mood and anxiety disorders and also the link between nutrition and psychiatry. Updates on new antipsychotics in schizophrenia and on the treatment of negative and depressive symptoms in schizophrenia will be presented. New studies on bipolar disorders have helped clarify the issues of treatment of bipolar depression and the associated cognitive impairment. An update on the risks of valproate will question its widespread use. A major current concern, which will be addressed in the meeting, is the apparent overuse of valproate in women of child bearing age. There will be sessions on anxiety disorders and a focus on long-term treatment and on comorbidity with alcohol dependence. We look forward to updates on the application of digital technology in psychiatry and the need for and use of rapid treatments for suicidality.

We look forward to seeing you all in Vienna for IFMAD 2019, to building strong professional contacts an expanding international network, to welcoming new participants and meeting our old friends, and discussing together the most important issues in this area of medicine!

A warm welcome from IFMAD chairmen!

Siegfried Kasper



lasses

Stuart Montgomery



Strass hotgons

**Eduard Vieta** 



Um

Allan Young



AND -



### **ACKNOWLEDGEMENTS**

For their contribution in supporting the poster presenters





For their contribution to the Scientific Programme



For their contribution to the Congress



### **SCIENTIFIC ADVISERS**

D. Baldwin (United Kingdom), B. Bandelow (Germany), M. Bauer (Germany), T. Dinan (Ireland), E. Eriksson (Sweden), N. Fineberg (United Kingdom), S. Kennedy (Canada), D. Lecic Tosevski (Serbia), A.A. Mathé (Sweden), H.J. Möller (Germany), S. Pallanti (Italy), J. Raboch (Czech Republic), Z. Rihmer (Hungary), A. Serretti (Italy), D.J. Stein (South Africa), T. Svensson (Sweden), D. Winkler (Austria), S. Yamawaki (Japan), J. Zohar (Israel)





### SCIENTIFIC PROGRAMME - Thursday, 04 July 2019

15h00 - 18h20	SCIENTIFIC SESSION – Chairs: S. KASPER – E. VIETA
15h00 - 15h40	SE. 01 Personalised treatment of TRD in practice Alexander Kautzky (Austria)
15h40 - 16h20	SE. 02 Nutritional psychiatry: focus on mood disorders Timothy Dinan (Ireland)
16h20 - 17h00	SE. 03 Treating cognitive dysfunction in mood disorders Eduard Vieta (Spain)
17h00 - 17h40	SE. 04 Advances in technology and digital psychiatry Diego Hidalgo-Mazzei (Spain)
17h40 - 18h20	On-line Survey Stuart Montgomery (United Kingdom)
18h30	OPENING RECEPTION

### SCIENTIFIC PROGRAMME - Friday, 05 July 2019

09h00 - 11h00	SCIENTIFIC SESSION – Chairs: T. DINAN - N. FINEBERG
09h00 - 09h40	SE. 05 Recent regulatory guidance about certain mood-stabilising medicines in women of child-bearing potential: are some prescriptions worth the risk?  David Baldwin (United Kingdom)
09h40 - 10h20	SE. 06 Therapeutic implications of including hypochondriasis in the ICD-11 Obsessive-Compulsive or Related Disorders (OCRDs)  Naomi Fineberg (United Kingdom)
10h20 - 11h00	SE. 07 Enduring effect of psychotherapy vs medication in anxiety disorders Borwin Bandelow (Germany)
11h00 - 11h30	COFFEE BREAK
11h30 - 12h30	SPONSORED SESSION
12h30 - 13h30	LUNCH







13h30 - 15h30	SCIENTIFIC SESSION – Chairs: B. BANDELOW - A. YOUNG
13h30 - 14h10	SE. 08 New findings on lithium Markus Dold (Austria)
14h10 - 14h50	SE. 09 Can we restore altered biological pathways in TRD starting from genetic findings? Chiara Fabbri (Italy)
14h50 - 15h30	SE. 10 Treatment of depressive and negative symptoms of schizophrenia Istvan Bitter (Hungary)
15h30 - 16h00	COFFEE BREAK
16h00 - 18h00	SCIENTIFIC SESSION – Chairs: A. SERRETTI - A. YOUNG
16h00 - 16h40	SE. 11 The role of anxiety in Baclofen treatment for alcohol dependence Julia Sinclair (United Kingdom)
16h40 - 17h20	SE. 12 Rapid Acting treatment in depression Siegfried Kasper (Austria)
17h20 - 18h00	SE. 13 Psychopharmacological approaches to Bipolar Depression Allan Young (United Kingdom)
18h00 - 18h30	KEYNOTE LECTURE – Chair: I. BITTER
18h00 - 18h30	Transcranial magnetic stimulation Stefano Pallanti (Italy)

### SCIENTIFIC PROGRAMME - Saturday, 06 July 2019

08h30 - 09h30	STROLLING POSTER SESSION AND COFFEE BREAK Chairs: S. MONTGOMERY - S. KASPER - A. YOUNG - S. PALLANTI
09h30 - 11h20	SCIENTIFIC SESSION – Chairs: C. FABBRI - S. MONTGOMERY
09h30 - 10h10	SE. 14 New antipsychotics in the treatment of depression Alessandro Serretti (Italy)
10h10 - 10h40	SE. 15 Inflammation in Affective Disorders Allan Young (United Kingdom)
10h40 - 11h20	SE. 16 Genetic testing in psychiatry: what clinicians need to know Chiara Fabbri (Italy)
11h20 - 12h15	CLOSING REMARKS - POSTER AWARDS AND FAREWELL COFFEE







### Industry Sponsored Lecture – Friday, 05 July 2019

DISCLAIMER: THE FOLLOWING LECTURE IS ORGANISED BY INDUSTRY. YOU CANNOT CLAIM CME CREDITS FOR ATTENDING THIS SESSION

11h30 - 12h30 SPONSORED SESSION

'How to manage patients with treatment resistant depression: could it also be ADHD?' Toni Ramos (Spain)

This lecture is organised and funded by Shire, now part of Takeda (and is intended for Healthcare Professionals only).





Imperial Riding School Renaissance Vienna Hotel







### **GENERAL INFORMATION**

### **AUDIO - VISUAL**

Equipment for computerized Power Point presentation is provided during the scientific sessions. Power Point presentations, CD-Rom or USB keys can be viewed and tested prior to presentation at the Speakers' Corner and must be handed over to the room technicians at least forty minutes before the beginning of the sessions and collected directly by the speakers immediately after. It is essential for the smooth running of the sessions that all Speakers hand in their presentation in due time.

#### **EUROPEAN ACCREDITATION**

The IFMAD Workshop has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC®s). To obtain your certificate please log I with your personal log-in credentials sent by mail on the website <a href="http://ifmad.org/">http://ifmad.org/</a>, and complete the questionnaire. Credits'certificates will be available from July 12<sup>th</sup>, 2019 to July 20<sup>th</sup>, 2019. After this date they will not be available anymore.

#### **CERTIFICATE OF ATTENDANCE**

The certificate of attendance will be downloadable from the website <u>www.ifmad.org</u> using your personal credentials sent by e-mail, starting from July 12<sup>th</sup>, 2019.

### **GOOD TO KNOW**

### **ADMISSION**

The participant's name badge are provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders are admitted to the appropriate sessions and Opening Reception.

#### **LANGUAGE**

The official language of the Congress is English. No simultaneous translation is provided.

The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to.

### **SECRETARIAT**

The secretariat desk opens on Thursday, 04 July 2019 and stays open all through the Congress.

#### **WELCOME COCKTAIL**

All delegates are cordially invited to attend the Opening Reception which is held on Thursday, 04 July at 18.30 at the **Imperial Riding School Hotel**.







### **POSTERS**

#### P.01 The basis of Ketamine action and its role on the treatment of Major Depressive Disorder

<u>Hugo Afonso</u>; Vera Froes<sup>1</sup>; Ivan Varela<sup>1</sup>; Sergio Esteves<sup>1</sup>; Miguel Carneiro<sup>1</sup>; Glaucia Lima<sup>1</sup> <sup>1</sup>Centro Hospitalar of Barreiro Montijo, Barreiro, Portugal

#### P.02 Practice of maintenance electroconvulsive therapy

<u>Jakub Albrecht</u><sup>1</sup>; Tadeas Mares<sup>1</sup>; Jozef Buday<sup>1</sup>; Gabriela Podgorna<sup>1</sup>; Jiri Raboch<sup>1</sup>; Martin Anders<sup>1</sup>

<u>Department of Psychiatry First Faculty of Medicine Charles University and General University Hospital, Prague, Czech Republic</u>

# P.03 The Impact of Suicidality on Major Depressive Disorder - Results from the European Group for the Study of Resistant Depression

<u>Lucie Bartova</u><sup>1</sup>; Markus Dold<sup>1</sup>; Gernot Fugger<sup>1</sup>; Alexander Kautzky<sup>1</sup>; Daniel Souery<sup>2,3</sup>; Julien Mendlewicz<sup>2</sup>; George N. Papadimitriou<sup>4</sup>; Dimitris Dikeos<sup>4</sup>; Panagiotis Ferentinos<sup>5</sup>; Stefano Porcelli<sup>6</sup>; Alessandro Serretti<sup>6</sup>; Joseph Zohar<sup>7</sup>; Stuart Montgomery<sup>8</sup>; Siegfried Kasper<sup>1</sup>

<sup>1</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; <sup>2</sup>School of Medicine, Free University of Brussels, Brussels, Belgium; <sup>3</sup>Psy Pluriel - European Centre of Psychological Medicine, Brussels, Belgium; <sup>4</sup>First Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece; <sup>5</sup>Second Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Attikon General Hospital, Athens, Greece; <sup>6</sup>Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; <sup>7</sup>Psychiatric Division, Chaim Sheba Medical Center, Tel Hashomer, Israel; <sup>8</sup>Imperial College, University of London, London, United Kingdom

# P.04 Spadin and shortened spadin analogs as efficient new antidepressants in mouse models of post-stroke depression

Marc Borsotto<sup>1</sup>; Mariel Pietri<sup>1</sup>; Alaeddine Djillani<sup>1</sup>; Jean Mazella<sup>1</sup>; Catherine Heurteaux<sup>1</sup>

<sup>1</sup>Centre National de la Recherche Scientifique, Institut De Pharmacologie Moléculaire et Cellulaire, UMR7275, Valbonne, France

# P.05 Comparison of depression, anxiety, and suicide ideation in transgender individuals based on their parents' reaction

Jinhyuk Choi1

<sup>1</sup>Bongseng memorial hospital, Busan, South Korea

#### P.06 Bipolar Disorder – Is gender important?

Ana Beatriz Cordeiro de Medeiros<sup>1</sup>; Cátia Fernandes Santos<sup>1</sup>; Magda Veiga Pereira<sup>1</sup>

<sup>1</sup>Serviço de Psiquiatria e Saúde Mental do Hospital Garcia de Orta, Almada, Portugal







#### P.07 Seasonal variation of benzodiazepine utilization among the Croatian population

Marija Delaš Aždajić<sup>1,3</sup>; Stjepan Aždajić<sup>1</sup>; Robert Likić<sup>2,3</sup>; Danijela Štimac Grbić<sup>3,4</sup>

<sup>1</sup>Sestre Milosrdnice University Hospital Center, Zagreb, Croatia; <sup>2</sup>University Hospital Centre Zagreb, Zagreb, Croatia; <sup>3</sup>School of Medicine, University of Zagreb, Zagreb, Croatia; <sup>4</sup>Croatian Institute of Public Health, Zagreb, Croatia

# P.08 Pharmacological management of acute mania: a 2-year retrospective study of prescription patterns in a portuguese acute psychiatric unit

<u>Cátia Fernandes Santos</u><sup>1</sup>; Ana Beatriz Medeiros<sup>1</sup>; Filipa Senos Moutinho<sup>1</sup>

# P.09 Cyberchondria as an emerging trans-diagnostic digital compulsive syndrome: An updated systematic review and clinical case report

Matteo Vismara<sup>1,2</sup>; Eduardo Cinosi<sup>1,3</sup>; Bernardo Dell'Osso<sup>2</sup>; Giovanni Martinotti<sup>3,4</sup>; Naomi A Fineberg<sup>1,3</sup>

<sup>1</sup>1 Hertfordshire Partnership University NHS Foundation Trust, Rosanne House, Welwyn Garden City, Hertfordshire, United Kingdom; <sup>2</sup>University of Milan, Department of Mental Health, Department of Biomedical and Clinical Sciences Luigi Sacco, Milan, Italy; <sup>3</sup>University of Hertfordshire, Hatfield, United Kingdom; <sup>4</sup>University G.d'Annunzio University, Department of Neuroscience, Imaging, Clinical Sciences,, Chieti-Pescara, Italy

# P.10 The study of the clinical and psychological characteristics of patients with anxious neurotic disorders in the course of analytical-cathartic therapy.

Evgenii Ilchenko1

<sup>1</sup>St. Petersburg "Hospital named after P.P. Kashchenko", Saint Petersburg, Russian Federation

### P.11 Pain behavior: new application of dire scale in patients with chronic pain syndromes

Olena Khaustova<sup>1</sup>

### P.12 Oriental herbal medicine for insomnia in elderly with hypertension: a systematic review and metaanalysis

SangHo Kim<sup>1</sup>

<sup>1</sup>Department of Neuropsychiatry of Korean Medicine, Pohang Korean Medicine Hospital Affiliated to Daegu Haany University, Pohang, South Korea

# P.13 Rapid augmentation of antipsychotic drugs by sodium nitroprusside (SNP). Behavioral assessment and effect on brain dopaminergic transmission in rats

Joep Titulaer<sup>1,2</sup>; Anna Malmerfelt<sup>2</sup>; Monica Marcus<sup>2</sup>; <u>Åsa Konradsson Geuken</u><sup>1,2</sup>; Alessia Perrone<sup>3</sup>; Giesbert Alken<sup>3</sup>; John Lowry<sup>4</sup>; Torgny Svensson<sup>2</sup>

<sup>1</sup>Uppsala University, Uppsala, Sweden; <sup>2</sup>Karolinska Institutet, Stockholm, Sweden; <sup>3</sup>BDD Drug Development GmbH, Berlin, Germany; <sup>4</sup>National University of Ireland Maynooth, Maynooth, Ireland



<sup>&</sup>lt;sup>1</sup>Department of Psychiatry and Mental Health, Hospital Garcia de Orta, Almada, Portugal

<sup>&</sup>lt;sup>1</sup>Bogomolets National Medical University, Kyiv, Ukraine





#### P.14 Association between cognitive functions and suicidal ideation in patients with mood disorder

<u>Suyeon Lee</u><sup>1</sup>; Woojae Myung<sup>1</sup>; Kichang Kim<sup>1</sup>; Sunghee Oh<sup>1</sup>; Nayoung Cho<sup>1</sup>; Yun seong Park<sup>1</sup>; Taewon Chung<sup>1</sup>; Hyun A Ryoo<sup>1</sup>; Tae Hyon Ha<sup>1</sup>

 $^{1}$ Department of Psychiatry, Seoul National University Bundang Hospital, Seongnam, South Korea

# P.15 Personalized psychotherapy system for depressive disorders, taking into account the prognosis factors of their course

Natalia Maruta<sup>1</sup>; Viktoriya Fedchenko<sup>1</sup>

#### P.16 Peculiarities of anxiety in the structure of mental health disorders of different genesis

Nataliya Maruta<sup>1</sup>; Tamara Panko<sup>1</sup>; Iryna Yavdak<sup>1</sup>; Galina Kalenskaya<sup>1</sup>; Oksana Maruta<sup>1</sup>

#### P.17 Menière's disease – a psychosomatic disorder?

Ana Beatriz Medeiros<sup>1</sup>; Filipe Correia<sup>2</sup>; Luís Castelhano<sup>2</sup>; Pedro Cavilhas<sup>2</sup>

## P.18 Is there abnormal functional connectivity between the cerebellum and the cerebrum networks in unmedicated patients with obsessive-compulsive disorder?

<u>Keitaro Murayama</u><sup>1</sup>; Tomohiro Nakao<sup>1</sup>; Tomiyama Hirofumi<sup>1</sup>; Hasuzawa Suguru<sup>1</sup>; Tsuruta Sae<sup>2</sup>; Ohno Aikana<sup>2</sup>

<sup>1</sup>Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

<sup>2</sup>Department of Clinical Psychology Practice, Graduate School of Human-Environment Studies, Kyushu University, Fukuoka, Japan

# P.19 Exposure to Ambient Fine Particles and Depressive Symptoms in Alzheimer Disease: CREDOS (Clinical Research Center for Dementia of South Korea) Study

Woojae Myung<sup>1</sup>; Hyewon Lee<sup>1,2</sup>; Hyeong-gwon An<sup>3</sup>

<sup>1</sup>Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, South Korea; <sup>2</sup>Institute of Health and Environment, Seoul National University, Seoul, South Korea; <sup>3</sup>Department of Psychiatry, CHA Bundang Medical Center, CHA University, Seongnam, South Korea

# P.20 Mobile app for the add-on treatment of generalized anxiety disorder and anxiety in mild to moderate depressive disorder – an assessment of need of patients and health care professionals

<u>Daniel Neto</u><sup>1,2</sup>; Carla Spínola<sup>3</sup>; Ana Ribeiro Moreira<sup>3</sup>; Teresa Castelo Branco<sup>2</sup>; Helena Sofia Pinto<sup>4</sup>; Joaquim Gago<sup>2,5</sup>
<sup>1</sup>Casa de Saúde São João de Deus,, Funchal, Portugal; <sup>2</sup>Clínica Grow Space, Lisboa, Portugal; <sup>3</sup>Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; <sup>4</sup>Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal; <sup>5</sup>Nova Medical School, Lisboa, Portugal



<sup>&</sup>lt;sup>1</sup>"Institute of neurology, psychiatry and narcology of NAMS of Ukraine" SI, Kharkiv, Ukraine

<sup>&</sup>lt;sup>1</sup>"Institute of Neurology, Psychiatry and Narcology of NAMS of Ukraine" SI, Kharkiv, Ukraine

<sup>&</sup>lt;sup>1</sup>Serviço de Psiquiatria e Saúde Mental do Hospital Garcia de Orta, Almada, Portugal; <sup>2</sup>Serviço de Neurologia do Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal





# P.21 The Effects of a Mobile Application using the MBSR technique on symptom relief of outpatients with panic disorder: A pilot study

Sunyoung Park<sup>1</sup>; Jungeun You<sup>2,3</sup>; Jungeun Song<sup>1</sup>

<sup>1</sup>Department of Psychiatry, National Health Insurance Service Ilsan Hospital, Goyang, South Korea; <sup>2</sup>Department of Psychology, Seoul National University, Seoul, South Korea; <sup>3</sup>MABO, Seoul, South Korea

#### P.22 Clinical Implication of Agoraphobia in the Patients with Panic Disorder

Jin Shin<sup>1</sup>; Jun Jeon Hong<sup>1</sup>

<sup>1</sup>Department of Psychiatry, Konkuk University Medical Center, Seoul, South Korea

#### P.23 Understanding the essence of Mood Disorders through the eyes of poetry

Gulbahar Sidhu<sup>1</sup>

<sup>1</sup>Doaba Hospital, Jalandhar, India

#### P.24 Lithium or valproate in Bipolar Disorder? A 3-Year Prospective Cohort Study

<u>Carla Spínola</u><sup>1</sup>; Daniel Neto<sup>2</sup>; Leonor Santana<sup>1</sup>; Filipe De Oliveira Azevedo<sup>1</sup>; Joaquim Gago<sup>1,3</sup>

<sup>1</sup>Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal; <sup>2</sup>Casa de Saúde São João de Deus, Funchal, Portugal; <sup>3</sup>Nova Medical School, Lisboa, Portugal

# P.25 Unique Pharmacology and Clinical Evidence Supporting the Antidepressant Therapeutic Potential of Lumateperone

<u>Joep Titulaer</u><sup>1,2</sup>; Robert Davies<sup>3</sup>; Sophie Dutheil<sup>3</sup>; Joseph Hendricks<sup>3</sup>; Lei Zhang<sup>3</sup>; Lawrence Wennogle<sup>3</sup>; Andrew Satlin<sup>3</sup>; Monica Marcus<sup>3</sup>; Sharon Mates<sup>3</sup>; Kim Vanover<sup>3</sup>; Gretchen Snyder<sup>3</sup>; Torgny Svensson<sup>2</sup>

1 Uppsala University, Uppsala, Sweden; <sup>2</sup>Karolinska Institutet, Stockholm, Sweden; <sup>3</sup>Intra Cellular Therapies, New York, USA









Tubii Creations

74 Bd d'Italie - 98000 - Monaco Ph. +377 97 97 35 55 - Fax +377 97 97 35 50 E-mail: ifmad@publicreations.com